Name of the Procedure:

Injection, Epoetin Alfa-epbx, Biosimilar, (Retacrit) (for non-ESRD use), 1000 Units (HCPCS Code: Q5106)

Summary

This procedure involves injecting a medication called Retacrit, which is a biosimilar to epoetin alfa, used to stimulate the production of red blood cells. It is administered to patients who do not have end-stage renal disease (non-ESRD) for various medical conditions that cause anemia.

Purpose

Retacrit is primarily used to treat anemia associated with conditions such as chronic kidney disease (non-ESRD), chemotherapy-induced anemia, and anemia related to other chronic diseases. The goal is to increase red blood cell count, thereby improving oxygen transport in the body and reducing symptoms of fatigue and weakness.

Indications

• Anemia due to chronic kidney disease (non-ESRD)
• Anemia caused by chemotherapy
• Anemia associated with other chronic conditions
• Low red blood cell counts (as determined by blood tests)

Preparation

• Follow the healthcare provider's instructions, which may include fasting or adjusting current medications.
• Blood tests to measure hemoglobin and iron levels.
• Ensure the patient is hydrated and has a functioning IV line if necessary.

Procedure Description

1. The healthcare provider will confirm the patient's identity and review their medical history.
2. The injection site, usually the abdomen or thigh, will be cleaned with an antiseptic.
3. A sterile syringe will be used to inject 1000 units of Retacrit subcutaneously.
4. The injection site may be gently massaged to ensure the medication is properly absorbed.
5. The procedure is carefully documented in the patient's medical records.

Duration

The injection itself takes only a few minutes to administer.

Setting

Administered in a doctor's office, outpatient clinic, or hospital setting.

Personnel

• Registered nurse or trained healthcare provider.
• Supervising physician or specialist.

Risks and Complications

• Common risks: Injection site reactions (redness, swelling, tenderness).
• Less common risks: Allergic reactions, high blood pressure, blood clots.
• Rare but serious risks: Seizures, increased risk of stroke or heart attack.

Benefits

• Increased red blood cell count.
• Improved energy levels and reduced symptoms of anemia.
• Better overall quality of life and ability to perform daily activities.

Recovery

• Minimal recovery time; patients can usually resume normal activities immediately.
• Keep the injection site clean and watch for signs of infection.
• Follow-up appointments to monitor blood counts and adjust dosage if necessary.

Alternatives

• Other erythropoiesis-stimulating agents (ESAs) like Procrit or Aranesp.
• Blood transfusions.
• Iron supplementation or alternative therapies depending on the cause of anemia.
• Pros: Immediate increase in hemoglobin with transfusions; Cons: Higher risk of complications with frequent transfusions.

Patient Experience

• Patients may feel a small pinch or sting during the injection.
• Slight discomfort or soreness at the injection site post-procedure.
• Effective pain management includes using over-the-counter analgesics if needed and applying a warm compress to the injection site.